High-level expression of hemoglobin A in human thalassemic erythroid progenitor cells following lentiviral vector delivery of an antisense snRNA

Blood

Volumn 101, Issue 1, 2003, Pages 104-111

  Vacek, Maria M ^a,b,c   Ma, Hong ^a,b,c   Gemignani, Federica ^a,b,c   Lacerra, Giuseppina ^a,b,c   Kafri, Tal ^a,b,c   Kole, Ryszard ^a,b,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; HEMOGLOBIN A; LENTIVIRUS VECTOR; MESSENGER RNA PRECURSOR; PROTEIN A; SMALL NUCLEAR RNA;

ARTICLE; BETA THALASSEMIA; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HELA CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INTRON; LENTIVIRUS BASED GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING;

EID: 0037217988     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1869     Document Type: Article

References (56)

1. Schwartz E, Benz EJ. Hematology: Basic Principles and Practice. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Thalassemia Syndromes. New York, NY: Churchill Livingston; 1991:586-610.
2. Rund D, Rachmilewitz E. New trends in the treatment of beta-thalassemia. Crit Rev Oncol Hematol. 2000;33:105-118.
3. Boulad F, Giardina P, Gillio A, et al. Bone marrow transplantation for homozygous beta-thalassemia. The Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci. 1998;850:498-502.
4. Lucarelli G, Galimberti M, Giardini C, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci. 1998;850:270-275.
5. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet. 1998;7:1655-1658.
6. Sadelain M. Globin gene transfer for the treatment of severe hemoglobinopathies: A paradigm for stem cell-based gene therapy. J Gene Med. 2002;4:113-121.
7. Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol. 2001;38:382-392.
8. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human betaglobin. Nature. 2000;406:82-86.
9. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood. 2002;99:1902-1908.
10. Sierakowska H, Gorman L, Kang SH, Kole R. Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing. Methods Enzymol. 2000;313:506-521.
11. Chui DH, Hardison R, Riemer C, et al. An electronic database of human hemoglobin variants on the World Wide Web. Blood. 1998;91:2643-2644.
12. Treisman R, Proudfoot NJ, Shander M, Maniatis T. A single-base change at a splice site in a beta 0-thalassemic gene causes abnormal RNA splicing. Cell. 1982;29:903-911.
13. Cheng TC, Orkin SH, Antonarakis SE, et al. beta-thalassemia in Chinese: Use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. Proc Natl Acad Sci U S A. 1984;81:2821-2825.
14. Dobkin C, Bank A. Reversibility of IVS 2 missplicing in a mutant human beta-globin gene. J Biol Chem. 1985;260:16332-16337.
15. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A. 1993;90:8673-8677.
16. Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci U S A. 1996;93:12840-12844.
17. Lacerra G, Sierakowska H, Carestia C, et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci U S A. 2000;97:9591-9596.
18. Gorman L, Suter D, Emerick V, Schumperli D, Kole R. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci U S A. 1998;95:4929-4934.
19. Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schumperli D. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human beta-thalassemic mutations. Hum Mol Genet. 1999;8:2415-2423.
20. Gorman L, Mercatante DR, Kole R. Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J Biol Chem. 2000;275:35914-35919.
21. Baserga SJ, Steitz JA. The diverse world of small ribonucleoproteins. In: Gesteland RF, Atkins, JF, eds. The RNA World. Plainview, NY: Cold Spring Harbor Laboratory Press; 1993:359-382.
22. Kafri T. Lentivirus vectors: Difficulties and hopes before clinical trials. Curr Opin Mol Ther. 2001;3:316-326.
23. Uchida N, Sutton RE, Friera AM, et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci U S A. 1998;95:11939-11944.
24. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A. 1999;96:2988-2993.
25. Chen W, Wu X, Levasseur DN, et al. Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated mice. Stem Cells. 2000;18:352-359.
26. + cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis. Hum Gene Ther. 2001;12:401-413.
27. Yamada K, Olsen JC, Patel M, Rao KW, Walsh CE. Functional correction of Fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. Mol Ther. 2001;3:485-490.
28. Saulnier SO, Steinhoff D, Dinauer MC, et al. Lentivirus-mediated gene transfer of gp91 phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells. J Gene Med. 2000;2:317-325.
29. Gemignani F, Landi S, DeMarini DM, Kole R. Spontaneous and MNNG-induced reversion of an EGFP construct in HeLa cells: An assay for observing mutations in living cells by fluorescent microscopy. Hum Mutat. 2001;18:526-534.
30. Sierakowska H, Sambade MJ, Schumperli D, Kole R. Sensitivity of splice sites to antisense oligonucleotides in vivo. RNA. 1999;5:369-377.
31. Sazani P, Kang SH, Maier MA, et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 2001;29:3965-3974.
32. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
33. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol. 1999;73:576-584.
34. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther. 2001;3:97-104.
35. Sun LQ, Pyati J, Smythe J, et al. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A. 1995;92:7272-7276.
36. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol. 1995;69:4045-4052.
37. Mautino MR, Morgan RA. Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA. Hum Gene Ther. 2000;11:2025-2037.
38. Sazani P, Vacek M, Kole, R. Modulation of gene expression by antisense therapeutics. Curr Opin Biotechnol. 2002;13:468-472.
39. Blencowe BJ. Exonic splicing enhancers: Mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci. 2000;25:106-110.
40. Liu HX, Chew SL, Cartegni L, Zhang MQ, Krainer AR. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol Cell Biol. 2000;20:1063-1071.
41. Lewis J, Yang B, Kim R, et al. Acommon human beta globin splicing mutation modeled in mice. Blood. 1998;91:2152-2156.
42. Suwanmanee T, Sierakowska H, Lacerra G, et al. Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol. 2002;62:545-553.
43. Papayannoupoulou T, Abkowitz J, D'Andrea A. Biology of erythropoiesis, erythroid differentiation, and maturation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 2000:202-219.
44. Yesilipek MA, Hazar V, Kupesiz A, Kizilors A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with beta-thalassemia. Bone Marrow Transplant. 2001;28:1037-1040.
45. Crooke ST. Basic principles of antisense technology. In: Crooke ST, ed. Antisense Drug Technology: Principles, Strategies and Applications. New York, NY: Marcel Dekker; 2001:1-28.
46. Krawczak M, Smith-Sorensen B, Schmidtke J, Kakkar VV, Cooper DN, Hovig E. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat. 1995;5:48-57.
47. Teraoka SN, Telatar M, Becker-Catania S, et al. Splicing defects in the ataxia-telangiectasia gene, ATM: Underlying mutations and consequences. Am J Hum Genet. 1999;64:1617-1631.
48. Ars E, Serra E, Garcia J, et al. Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet. 2000;9:237-247.
49. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem. 1999;274:36193-36199.
50. Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999;9:330-338.
51. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A. 2001;98:42-47.
52. Kalbfuss B, Mabon SA, Misteli T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem. 2001;276:42986-42993.
53. Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem. 2001;276:45476-45483.
54. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol. 1999;17:1097-1100.
55. Grimm C, Stefanovic B, Schumperli D. The low abundance of U7 snRNA is partly determined by its Sm binding site. EMBO J. 1993;12:1229-1238.
56. Mercatante DR, Bortner CD, Cidlowski JA, Kole R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells; analysis of apoptosis and cell death. J Biol Chem. 2001;276:16411-16417.